JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Case Report
Isolated myeloid sarcoma causing obstructive jaundice in duodenal ampulla: a very rare case
Abstract
Isolated myeloid sarcoma (MS) is a malignant neoplasm of myeloid origin that is located in extramedullary tissues. MS is rare; only 5–6% of MS cases originate from the gastrointestinal tract (GIT). These patients usually present with non–specific symptoms associated with the GIT, thus, the diagnosis is easily overlooked and patients are misdiagnosed. Established treatment options for MS include local therapies (surgery or radiotherapy or a combination), systemic chemotherapy, allogeneic hematopoietic stem–cell transplantation (HSCT), and targeted therapies. In this article, we present a case of isolated MS localized in the duodenal ampulla that presented with cholestatic jaundice. On magnetic resonance imaging (MRI) and MR cholangiography (MRCP), a 3.8×3.5 cm mass lesion was visualized in the duodenal ampulla. A diagnosis of MS was made based on an endoscopic retrograde cholangiopancreatography biopsy. It was recognized as an isolated MS after further examination. An idarubicin and cytarabine–based chemotherapy regimen were administered for induction and allogeneic HSCT was administered as post–remission consolidation therapy. The patient remains in remission under follow–up in the 6th month after allogeneic HSCT. Isolated MS is a rare hematologic neoplasia comprised of immature granulocytic cells. Although it can be detected in any part of the body, hepatobiliary, and particularly, pancreatic involvement is much less frequent. The optimal treatment of the disease is not elucidated due to the lack of relevant data and large prospective studies in the literature. The most recommended treatments are the systemic chemotherapies used in AML remission induction treatment. The authors think that allogeneic HSCT must be considered after the induction of remission in MS, as it offers an advantage in terms of overall survival and leukemia–free survival.

Keywords : Myeloid sarcoma, duodenal ampulla, pancreas, hepatobiliary, granulocytic sarcoma

Download Article


1. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010;184(1-2): 16-20. doi:10.1016/j.cbi.2009.10.009
2. Claerhout H, Van Aelst S, Melis C, et al. Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study. Eur J Haematol. 2018;100(6):603-612. doi:10.1111/ejh.13056
3. Pileri SA, Ascani S, Cox MC, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340-350. doi:10.1038/sj.leu.2404491
4. Patkowska E, Krzywdzinska A, Solarska I, Wojtas M, Prochorec-Sobieszek M. Diagnostic approaches in myeloid sarcoma. Curr Issues Mol Biol. 2025;47(2):111. doi:10.3390/cimb47020111
5. Goyal G, Bartley AC, Patnaik MM, Litzow MR, Al-Kali A, Go RS. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J. 2017;7(8):e592. doi:10.1038/bcj.2017.79
6. Meyer HJ, Pönisch W, Schmidt SA, et al. Clinical and imaging features of myeloid sarcoma: a German multicenter study. BMC Cancer. 2019; 19(1):1150. doi:10.1186/s12885-019-6357-y
7. Movassaghian M, Brunner AM, Blonquist TM, et al. Presentation and outcomes among patients with isolated myeloid sarcoma: a surveillance, epidemiology, and end results database analysis. Leuk Lymphoma. 2015; 56(6):1698-1703. doi:10.3109/10428194.2014.963080
8. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785-3793. doi:10.1182/blood-2011-04-347229
9. Li XP, Liu WF, Ji SR, Wu SH, Sun JJ, Fan YZ. Isolated pancreatic granulocytic sarcoma: a case report and review of the literature. World J Gastroenterol. 2011;17(4):540-542. doi:10.3748/wjg.v17.i4.540
10. Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma. 2006;47(12):2527-2541. doi:10. 1080/10428190600967196
11. Antic D, Elezovic I, Milic N, et al. Is there a “gold” standard treatment for patients with isolated myeloid sarcoma? Biomed Pharmacother. 2013;67(1):72-77. doi:10.1016/j.biopha.2012.10.014
12. Stölzel F, Röllig C, Radke J, et al. ¹8F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia. Haematologica. 2011;96(10): 1552-1556. doi:10.3324/haematol.2011.045047
13. Sun J, Zhang YC, Wei J, et al. Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study. Bone Marrow Transplant. 2025;60(3):319-325. doi:10.1038/s41409-024-02485-y
Article available in :
Volume 3, Issue 4, 2025
Page : 100-102
https://doi.org/10.51271/JCHOR-0071
Article Information
Received : 28 May 2025
Accepted : 18 Eyl 2025
Published : 13 Kas 2025
Corresponding Author :

Ömer Candar: Department of Hematology, Eskişehir City Hospital, Eskişehir, Turkiye

[email protected]
Citation : Candar Ö, Ekinci Ö, Merter M, Aslan M, Çalık İ. Isolated myeloid sarcoma causing obstructive jaundice in duodenal ampulla: a very rare case. J Curr Hematol Oncol Res. 2025;3(4):100-102.

Read: 64
Download : 60
Cited: 0
_Footer